Hypogammaglobulinemia and Infection Risk in an Ocrelizumab-treated Multiple Sclerosis Cohort. Nobile S, Beauchemin P. Can J Neurol Sci 2024 Feb 12:1-21. doi: 10.1017/cjn.2024.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nobile S, Beauchemin P. Hypogammaglobulinemia and Infection Risk in an Ocrelizumab-treated Multiple Sclerosis Cohort. Can J Neurol Sci 2024 Feb 12:1-21. doi: 10.1017/cjn.2024.
PMID: 38343112